HIGHLIGHTS
- who: Kenichi Nishimura and collaborators from the Department of Urology, Ehime University Graduate School of Medicine, Toon, Japan have published the article: CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma, in the Journal: (JOURNAL)
- what: The aim of this study was to elucidate early B cell changes after CCB therapy in patients with renal cell carcinoma (RCC) and verify whether B cells can be a predictor of irAEs. The reason for the slower increase in CD21lo B cells in the study compared to the study by . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.